Related Experiment Video
Updated: May 18, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
[Dutch guideline for cardiovascular risk management: a consensus model]
1Maastricht Universitair Medisch Centrum, afd. Interne Geneeskunde, Maastricht, the Netherlands. aa.kroon@mumc.nl
Insights
This commentary reviews hypertension treatment guidelines, emphasizing age-related cardiovascular risk and considering hyperlipidemia management in obesity and diabetes. It suggests measuring apolipoprotein B-100 or non-HDL cholesterol for targeted interventions.
Area of Science:
- Cardiology
- Endocrinology
- Public Health
Background:
- The 2011 hypertension guideline revision is based on a consensus model.
- Recent studies highlight the importance of age in cardiovascular risk stratification.
- Hyperlipidemia in obesity and diabetes requires specific screening and treatment considerations.
Purpose of the Study:
- To discuss the role of age in cardiovascular risk stratification for hypertension.
- To evaluate the significance of hyperlipidemia management in obese and diabetic patients.
- To advocate for specific lipid measurements in clinical practice.
Main Methods:
- Commentary and analysis of existing guideline data.
- Review of recent scientific literature on hypertension and hyperlipidemia.
- Discussion of consensus-based recommendations.
Main Results:
- Hypertension treatment should be considered for both very old and very young individuals.
- Apolipoprotein B-100 or non-HDL cholesterol measurement is recommended for screening and treatment targets in hyperlipidemia.
- The guideline revision reflects a consensus approach to cardiovascular risk management.
Conclusions:
- Age is a critical factor in cardiovascular risk stratification and hypertension management.
- Specific lipid markers are essential for effective hyperlipidemia treatment in at-risk populations.
- The discussed aspects of the guideline aim to improve patient outcomes in cardiovascular and metabolic diseases.
Abstract:
This commentary concerns two major aspects of the guideline, which was revised in 2011 and seems to us the result of a consensus model. The first aspect, namely, of age in relation to cardiovascular risk stratification and the indication that recent studies show that treatment of hypertension of both very old and young people should be considered, is discussed. The second aspect discussed in this commentary, regarding hyperlipidaemia in obesity and diabetes, concerns the argument that apolipoprotein B-100 level or non-HDL cholesterol should specifically be measured for screening and treatment targets.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Rheumatic Heart Disease III: Medical Management
Pre-Procedural Guidelines for Assessing Blood Pressure
Heart Failure V: Medical Management
Rheumatic Heart Disease IV: Nursing Management